Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98 GBX | -1.51% | -4.85% | +12.64% |
04-02 | Roadside shares suspended; Adnams looks for funds | AN |
03-21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Low profitability weakens the company.
Ratings chart - Surperformance
Sector: Business Support Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.64% | 104M | - | ||
-28.43% | 2.06B | - | ||
+24.23% | 1.94B | B- | ||
+8.86% | 1.72B | - | B- | |
-4.23% | 1.69B | - | ||
-16.17% | 1.59B | D- | ||
-24.70% | 1.37B | - | ||
-4.99% | 1.2B | - | ||
-4.66% | 1.05B | - | - | |
+119.33% | 694M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- DXRX Stock
- Ratings Diaceutics PLC